Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier
I'm LongbridgeAI, I can summarize articles.Edgewise Therapeutics completed the sale of its sevasemten compound and muscular dystrophy business to Servier Pharmaceuticals for up to $2.65 billion. The deal transfers all rights and staff to Servier, strengthening Edgewise's balance sheet and allowing it to focus on cardiovascular assets. Analysts rate EWTX as a Buy with a $51 price target, while TipRanks' AI suggests Neutral due to mixed fundamentals despite the strategic boost from the asset sale.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Edgewise Therapeutics ( (EWTX) ) just unveiled an announcement.
On July 10, 2026, Edgewise Therapeutics completed the sale of its sevasemten compound and muscular dystrophy business to Servier Pharmaceuticals for $1.55 billion in upfront cash and up to $1.1 billion in milestone payments, for potential total consideration of $2.65 billion. The deal transfers all sevasemten rights, IP, data and core program staff to Servier, which aims to build a rare neurology franchise while continuing late-stage development in Becker and Duchenne muscular dystrophy.
Announced publicly on July 13, 2026, the transaction significantly strengthens Edgewise’s balance sheet and consolidates its strategy as a cardiovascular-focused company built around lead assets EDG-7500, EDG-15400 and EDG-003. Edgewise expects the upfront proceeds, combined with existing cash, to fully fund EDG-7500 through potential approval and support broader cardiovascular pipeline expansion, while Servier gains a late-stage, regulatorily de-risked muscular dystrophy asset with orphan and rare pediatric designations and ongoing pivotal trials.
The most recent analyst rating on (EWTX) stock is a Buy
with a $51.00 price target.
To see the full list of analyst forecasts on Edgewise Therapeutics stock,
see the EWTX Stock Forecast page.
Spark’s Take on EWTX Stock
According to Spark, TipRanks’ AI Analyst, EWTX is a Neutral.
The score is primarily driven by mixed financial fundamentals: a strong, low-debt balance sheet is a meaningful positive, but it is offset by being pre-revenue with large, persistent losses and heavy cash burn. Technically, the stock is in a strong uptrend, though momentum indicators suggest it may be overextended. Valuation remains weak due to negative earnings and no dividend support, while the recent asset-sale event provides a significant near-term balance-sheet and strategic boost.
To see Spark’s full report on EWTX stock,
click here.
More about Edgewise Therapeutics
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in novel, muscle-targeted small-molecule therapeutics, with a growing focus on cardiovascular diseases. The Boulder, Colo.-based firm is advancing a pipeline aimed at significant unmet needs such as hypertrophic cardiomyopathy, heart failure with preserved ejection fraction and other serious cardiovascular and cardiometabolic conditions.
Average Trading Volume: 1,474,763
Technical Sentiment Signal: Buy
Current Market Cap: $4.89B
For a thorough assessment of EWTX stock, go to TipRanks’ Stock Analysis page.